Skip to content

EMA publishes background documents on proposed medicines safety research topics and priorities

The European Medicines Agency (EMA) has published background information in relation to 3 medicines safety topics that the European Commission has indicated it may fund research in.
Every year the EMA gives the Commission a list of suggested research priorities on medicine safety based on the considerations of the EMA’s Committee for Medicinal Products for Human Use (CHMP).

Subsequent to EMA’s suggestions of November 2011 an orientation paper published by the Commission in April 2012 (see EU Monitor 13 April /News/EU-Monitor/EU-Monitor-13-April-2012) indicated 3 EMA subject recommendations will now be considered European research priorities for funding:

  • Long-term safety effects of antipsychotics in patients with dementia;
  • Long-term adverse skeletal effects of bisphosphonates;
  • DNA collection and studies on the genetic causes of adverse drug reactions: angiotensin-converting enzyme inhibitor-related angioedema and statin-induced myopathy.

To support research proposals the EMA has now published background information documents about the 3 medicines safety topics, outlining previous EMA considerations in the areas and why, and in relation to what aspects, EMA consider further research is required.
 

More information here.
 

×

EAHP Forum

All the EAHP team is working on providing a Forum that can help connect all the members in Conversations and Groups to talk about important matters for the European Hospital Pharmacist.

The Forum will be accessible for all the EAHP members, you don’t have to create a new account to browse and participate.

Conversations and groups

The Conversations will be moderated by our team to provide documents and relevant topics for the community.

The Groups will connect all members that share a category. Members who work on the same assocation, on the same hospital, that have the same role, etc.

Stay tuned for the realase of the forum. Soon on EAHP.